CTOR (Citius Oncology) Research & Development : $ Mil (TTM As of Sep. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Citius Oncology's Research & Development for the six months ended in Sep. 2023 was $4.24 Mil. Citius Oncology does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Sep. 2023.

Citius Oncology Research & Development Historical Data

The historical data trend for Citius Oncology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Research & Development Chart

Citius Oncology Annual Data

Trend

Sep22

Research & Development

3.43

Citius Oncology Semi-Annual Data
	Sep22	Sep23
Research & Development	3.43	4.24

Citius Oncology Research & Development Calculation

This is the expense the company spent on research and development.

Citius Oncology (NAS:CTOR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Citius Oncology Research & Development Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Ave, Suite 2446, New York, NY, USA, 10170

Website

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.